文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Ability of F-FDG Positron Emission Tomography Radiomics and Machine Learning in Predicting KRAS Mutation Status in Therapy-Naive Lung Adenocarcinoma.

作者信息

Zhang Ruiyun, Shi Kuangyu, Hohenforst-Schmidt Wolfgang, Steppert Claus, Sziklavari Zsolt, Schmidkonz Christian, Atzinger Armin, Hartmann Arndt, Vieth Michael, Förster Stefan

机构信息

Institute of Pathology, Medizincampus Oberfranken, Klinikum Bayreuth, Friedrich-Alexander-Universität Erlangen-Nürnberg, 95445 Bayreuth, Germany.

Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.

出版信息

Cancers (Basel). 2023 Jul 19;15(14):3684. doi: 10.3390/cancers15143684.


DOI:10.3390/cancers15143684
PMID:37509345
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10377773/
Abstract

OBJECTIVE: Considering the essential role of KRAS mutation in NSCLC and the limited experience of PET radiomic features in KRAS mutation, a prediction model was built in our current analysis. Our model aims to evaluate the status of KRAS mutants in lung adenocarcinoma by combining PET radiomics and machine learning. METHOD: Patients were retrospectively selected from our database and screened from the NSCLC radiogenomic dataset from TCIA. The dataset was randomly divided into three subgroups. Two open-source software programs, 3D Slicer and Python, were used to segment lung tumours and extract radiomic features from F-FDG-PET images. Feature selection was performed by the Mann-Whitney U test, Spearman's rank correlation coefficient, and RFE. Logistic regression was used to build the prediction models. AUCs from ROCs were used to compare the predictive abilities of the models. Calibration plots were obtained to examine the agreements of observed and predictive values in the validation and testing groups. DCA curves were performed to check the clinical impact of the best model. Finally, a nomogram was obtained to present the selected model. RESULTS: One hundred and nineteen patients with lung adenocarcinoma were included in our study. The whole group was divided into three datasets: a training set ( = 96), a validation set ( = 11), and a testing set ( = 12). In total, 1781 radiomic features were extracted from PET images. One hundred sixty-three predictive models were established according to each original feature group and their combinations. After model comparison and selection, one model, including wHLH_fo_IR, wHLH_glrlm_SRHGLE, wHLH_glszm_SAHGLE, and smoking habits, was validated with the highest predictive value. The model obtained AUCs of 0.731 (95% CI: 0.6190.843), 0.750 (95% CI: 0.2481.000), and 0.750 (95% CI: 0.448~1.000) in the training set, the validation set and the testing set, respectively. Results from calibration plots in validation and testing groups indicated that there was no departure between observed and predictive values in the two datasets ( = 0.377 and 0.861, respectively). CONCLUSIONS: Our model combining F-FDG-PET radiomics and machine learning indicated a good predictive ability of KRAS status in lung adenocarcinoma. It may be a helpful non-invasive method to screen the KRAS mutation status of heterogenous lung adenocarcinoma before selected biopsy sampling.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc6a/10377773/487269269231/cancers-15-03684-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc6a/10377773/65cf88717b24/cancers-15-03684-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc6a/10377773/99a54b03adcc/cancers-15-03684-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc6a/10377773/e1613d52bf61/cancers-15-03684-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc6a/10377773/487269269231/cancers-15-03684-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc6a/10377773/65cf88717b24/cancers-15-03684-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc6a/10377773/99a54b03adcc/cancers-15-03684-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc6a/10377773/e1613d52bf61/cancers-15-03684-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc6a/10377773/487269269231/cancers-15-03684-g004.jpg

相似文献

[1]
Ability of F-FDG Positron Emission Tomography Radiomics and Machine Learning in Predicting KRAS Mutation Status in Therapy-Naive Lung Adenocarcinoma.

Cancers (Basel). 2023-7-19

[2]
Machine learning based on clinico-biological features integrated F-FDG PET/CT radiomics for distinguishing squamous cell carcinoma from adenocarcinoma of lung.

Eur J Nucl Med Mol Imaging. 2021-5

[3]
Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.

Mol Imaging Biol. 2020-8

[4]
PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs.

Front Oncol. 2022-6-21

[5]
Value of pre-therapy F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer.

Eur J Nucl Med Mol Imaging. 2020-5

[6]
Predicting EGFR mutation subtypes in lung adenocarcinoma using F-FDG PET/CT radiomic features.

Transl Lung Cancer Res. 2020-6

[7]
A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts ALK Rearrangement Status in Lung Adenocarcinoma.

Front Oncol. 2021-3-2

[8]
Radiomics analysis for the differentiation of autoimmune pancreatitis and pancreatic ductal adenocarcinoma in F-FDG PET/CT.

Med Phys. 2019-8-13

[9]
The predictive value of [F]FDG PET/CT radiomics combined with clinical features for EGFR mutation status in different clinical staging of lung adenocarcinoma.

EJNMMI Res. 2023-4-4

[10]
Impact of feature harmonization on radiogenomics analysis: Prediction of EGFR and KRAS mutations from non-small cell lung cancer PET/CT images.

Comput Biol Med. 2022-3

引用本文的文献

[1]
Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods.

Eur Radiol. 2025-9-8

[2]
From Images to Genes: Radiogenomics Based on Artificial Intelligence to Achieve Non-Invasive Precision Medicine in Cancer Patients.

Adv Sci (Weinh). 2025-1

[3]
Does FDG PET-Based Radiomics Have an Added Value for Prediction of Overall Survival in Non-Small Cell Lung Cancer?

J Clin Med. 2024-4-29

本文引用的文献

[1]
A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133.

Cancer Res. 2023-9-1

[2]
The pharmacologic and toxicologic characterization of the potent and selective KRAS G12D inhibitors ERAS-4693 and ERAS-5024.

Toxicol Appl Pharmacol. 2023-9-1

[3]
Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation.

Cancers (Basel). 2021-7-16

[4]
Integration of clinicopathological and mutational data offers insight into lung cancer with tumor spread through air spaces.

Ann Transl Med. 2021-6

[5]
Pretreatment F-FDG PET/CT Imaging Predicts the KRAS/NRAS/BRAF Gene Mutational Status in Colorectal Cancer.

J Oncol. 2021-6-18

[6]
Sotorasib for Lung Cancers with p.G12C Mutation.

N Engl J Med. 2021-6-24

[7]
A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC.

Tomography. 2021-4-29

[8]
Simultaneous Identification of and Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics.

Cancers (Basel). 2021-4-10

[9]
The Prevalence and Concurrent Pathogenic Mutations of in Northeast Chinese Non-small-cell Lung Cancer Patients.

Cancer Manag Res. 2021-3-15

[10]
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

CA Cancer J Clin. 2021-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索